Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study.
OBJECTIVE
The effect of basiliximab induction therapy on long-term patient and graft survival is not yet clear. We aimed to evaluate if there is any advantage of routine basiliximab induction on the long-term outcome of living related donor kidney transplantation.


METHODS
One hundred adult recipients with their first kidney allograft were randomized into two treatment groups, one group received basiliximab and the second served as a control. All patients received a maintenance triple immunosuppressive therapy (steroids, cyclosporine (CsA) micro-emulsion and azathioprine) and were followed up thoroughly for 7 years.


RESULTS
Basiliximab significantly reduced the proportion of patients who experienced acute rejection in the first year (18/50) when compared to the control group (31/50), and in 7 years (28/50) when compared to (37/50) in controls. The cumulative steroid dose used throughout the whole study period was significantly lower in the basiliximab group. The overall incidence of post-transplant complications was comparable among the two treatment groups. There was no significant difference in patient or graft survival; 7 years patient and graft survival were 92, 76% for basiliximab and 92, 80% for the control group, respectively.


CONCLUSIONS
Routine basiliximab induction significantly reduced the incidence of acute rejection without any noticeble beneficial effect on the long-term renal transplantation outcome.
Sheashaa
Hussein A
HA
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. drhattia@yahoo.com.
Bakr
Mohamed A
MA
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ismail
Amani M
AM
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mahmoud
Khaled M
KM
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Sobh
Mohamed A
MA
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ghoneim
Mohamed A
MA
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D000077552:Basiliximab; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology; D019520:Living Donors; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D013256:Steroids; D016572:Cyclosporine; D000077552:Basiliximab; D001379:Azathioprine